175 related articles for article (PubMed ID: 23815529)
1. Is it variants in the apolipoprotein l1 gene, or blood pressure control, that predicts progression of nondiabetic hypertensive nephropathy in African Americans?
Cohen DL; Townsend RR
J Clin Hypertens (Greenwich); 2013 Jul; 15(7):445-6. PubMed ID: 23815529
[No Abstract] [Full Text] [Related]
2. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.
Lipkowitz MS; Freedman BI; Langefeld CD; Comeau ME; Bowden DW; Kao WH; Astor BC; Bottinger EP; Iyengar SK; Klotman PE; Freedman RG; Zhang W; Parekh RS; Choi MJ; Nelson GW; Winkler CA; Kopp JB;
Kidney Int; 2013 Jan; 83(1):114-20. PubMed ID: 22832513
[TBL] [Abstract][Full Text] [Related]
3. Hypertension-misattributed kidney disease in African Americans.
Skorecki KL; Wasser WG
Kidney Int; 2013 Jan; 83(1):6-9. PubMed ID: 23271482
[TBL] [Abstract][Full Text] [Related]
4. Re-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression.
Hawkins GA; Friedman DJ; Lu L; McWilliams DR; Chou JW; Sajuthi S; Divers J; Parekh RS; Li M; Genovese G; Pollack MR; Hicks PJ; Bowden DW; Ma L; Freedman BI; Langefeld CD
Am J Nephrol; 2015; 42(2):99-106. PubMed ID: 26343748
[TBL] [Abstract][Full Text] [Related]
5. Target organ damage in African American hypertension: role of APOL1.
Freedman BI; Murea M
Curr Hypertens Rep; 2012 Feb; 14(1):21-8. PubMed ID: 22068337
[TBL] [Abstract][Full Text] [Related]
6. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.
Freedman BI; Langefeld CD; Andringa KK; Croker JA; Williams AH; Garner NE; Birmingham DJ; Hebert LA; Hicks PJ; Segal MS; Edberg JC; Brown EE; Alarcón GS; Costenbader KH; Comeau ME; Criswell LA; Harley JB; James JA; Kamen DL; Lim SS; Merrill JT; Sivils KL; Niewold TB; Patel NM; Petri M; Ramsey-Goldman R; Reveille JD; Salmon JE; Tsao BP; Gibson KL; Byers JR; Vinnikova AK; Lea JP; Julian BA; Kimberly RP;
Arthritis Rheumatol; 2014 Feb; 66(2):390-6. PubMed ID: 24504811
[TBL] [Abstract][Full Text] [Related]
7. The new era of APOL1-associated glomerulosclerosis.
Freedman BI; Langefeld CD
Nephrol Dial Transplant; 2012 Apr; 27(4):1288-91. PubMed ID: 22302261
[No Abstract] [Full Text] [Related]
8. APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease.
Ma L; Langefeld CD; Comeau ME; Bonomo JA; Rocco MV; Burkart JM; Divers J; Palmer ND; Hicks PJ; Bowden DW; Lea JP; Krisher JO; Clay MJ; Freedman BI
Kidney Int; 2016 Aug; 90(2):389-395. PubMed ID: 27157696
[TBL] [Abstract][Full Text] [Related]
9. Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease.
Anyaegbu EI; Shaw AS; Hruska KA; Jain S
Pediatr Nephrol; 2015 Jun; 30(6):983-9. PubMed ID: 25530085
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein l1 and the genetic basis for racial disparity in chronic kidney disease.
Quaggin SE; George AL
J Am Soc Nephrol; 2011 Nov; 22(11):1955-8. PubMed ID: 21997393
[No Abstract] [Full Text] [Related]
11. APOL1 and kidney disease: new insights leading to novel therapies.
Freedman BI
Am J Kidney Dis; 2015 Jul; 66(1):9-11. PubMed ID: 26111904
[No Abstract] [Full Text] [Related]
12. APOL1 risk variants, race, and progression of chronic kidney disease.
Parsa A; Kao WH; Xie D; Astor BC; Li M; Hsu CY; Feldman HI; Parekh RS; Kusek JW; Greene TH; Fink JC; Anderson AH; Choi MJ; Wright JT; Lash JP; Freedman BI; Ojo A; Winkler CA; Raj DS; Kopp JB; He J; Jensvold NG; Tao K; Lipkowitz MS; Appel LJ; ;
N Engl J Med; 2013 Dec; 369(23):2183-96. PubMed ID: 24206458
[TBL] [Abstract][Full Text] [Related]
13. The Apolipoprotein L1 Gene and Cardiovascular Disease.
Robinson TW; Freedman BI
Methodist Debakey Cardiovasc J; 2016; 12(4 Suppl):2-5. PubMed ID: 28298955
[TBL] [Abstract][Full Text] [Related]
14. APOL1 and progression of nondiabetic nephropathy.
Palmer ND; Freedman BI
J Am Soc Nephrol; 2013 Sep; 24(9):1344-6. PubMed ID: 23813212
[No Abstract] [Full Text] [Related]
15. Intensive blood-pressure control in hypertensive chronic kidney disease.
Freedman BI; Sedor JR
N Engl J Med; 2010 Dec; 363(26):2565; author reply 2565-6. PubMed ID: 21175324
[No Abstract] [Full Text] [Related]
16. Gene-gene and gene-environment interactions in apolipoprotein L1 gene-associated nephropathy.
Freedman BI; Skorecki K
Clin J Am Soc Nephrol; 2014 Nov; 9(11):2006-13. PubMed ID: 24903390
[TBL] [Abstract][Full Text] [Related]
17.
Chen TK; Appel LJ; Grams ME; Tin A; Choi MJ; Lipkowitz MS; Winkler CA; Estrella MM
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1765-1769. PubMed ID: 28572159
[TBL] [Abstract][Full Text] [Related]
18. Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression.
Chen TK; Choi MJ; Kao WH; Astor BC; Scialla JJ; Appel LJ; Li L; Lipkowitz MS; Wolf M; Parekh RS; Winkler CA; Estrella MM; Crews DC
Clin J Am Soc Nephrol; 2015 Dec; 10(12):2128-35. PubMed ID: 26430087
[TBL] [Abstract][Full Text] [Related]
19. Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder.
Kopp JB
Curr Opin Nephrol Hypertens; 2013 May; 22(3):266-72. PubMed ID: 23470819
[TBL] [Abstract][Full Text] [Related]
20. Population-based risk assessment of APOL1 on renal disease.
Friedman DJ; Kozlitina J; Genovese G; Jog P; Pollak MR
J Am Soc Nephrol; 2011 Nov; 22(11):2098-105. PubMed ID: 21997396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
